Boston Scientific Announces Agreement to Acquire Axonics, Inc.

Boston Scientific Corporation (NYSE: BSX) announces it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. The purchase price is $71 in cash per share, reflecting an equity value of approximately $3.7 billion and an enterprise value of approximately $3.4 billion. The Axonics product portfolio includes the Axonics R20TM and the Axonics F15TM Systems used to deliver sacral neuromodulation (SNM) therapy. SNM therapy is a minimally invasive procedure used in the treatment of OAB and fecal incontinence.

Read the full article: Boston Scientific Announces Agreement to Acquire Axonics, Inc. //

Source: https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-axonics-inc-302027843.html

Leave a Comment

Your email address will not be published.

Scroll to Top